62 results about "Estrogenic Effects" patented technology

Extracts of various species of the Moraceae family have estrogenic properties. For example, aqueous and ethanolic extracts of Morus alba L. species possess estrogenic properties in both ERα+ and ERβ+ cells. These estrogenic effect include estrogen response element (ERE) stimulation as well as tumor necrosis factor (TNF) repression. Methods are provided for treating climacteric symptoms, breast and / or uterine cancer, and osteoporosis.

Extracts of various species of the Moraceae family have estrogenic properties. For example, aqueous and ethanolic extracts of Morus alba L. species possess estrogenic properties in both ERα+ and ERβ+ cells. These estrogenic effect include estrogen response element (ERE) stimulation as well as tumor necrosis factor (TNF) repression. Methods are provided for treating climacteric symptoms, breast and / or uterine cancer, and osteoporosis.

Extracts of various species of the Leguminosae family have estrogenic properties. For example, aqueous and ethanolic extracts of Pueraria lobata Willd. Ohwi of the Leguminosae family species possess estrogenic properties in both ERα+ and ERβ+ cells. These estrogenic effects include estrogen response element (ERE) stimulation as well as tumor necrosis factor (TNF) repression. Methods are provided for treating climacteric symptoms, breast and / or uterine cancer, and osteoporosis.

Methods are provided for preventing or treating risk factors for cardiovascular disease in an individual, comprising administering a therapeutically effective amount of a composition comprising an estradiol metabolite to said individual. Such risk factors include obesity, the metabolic syndrome, diabetes mellitus, vascular disorders, and renal disorders. Preferred estradiol metabolites include 2-methoxyestradiol, 4-methoxyestradiol, 2-hydroxyestradiol, and 4-hydroxyestradiol or prodrugs thereof. The compositions may also be in the form of a controlled release formulation. Methods are also provided for use of estradiol metabolites to treat or prevent insulin resistance, vascular endothelial dysfunction, hyperlipidemia, hypertension, diabetic nephropathy, proteinuria and reducing leptin levels. In addition, the methods provide a method of stabilizing glucose levels. These treatments may be used in either gender because of their lack of a feminizing estrogenic effect.

Estrogenic compositions comprising calycosin and analogs thereof are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.

Estrogenic compositions comprising nyasol and analogs thereof are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.

Estrogenic extracts of Asparagus conchinchinensis (Lour.) Merr of the Liliaceae Family are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.

Extracts of various species of the Moraceae family have estrogenic properties. For example, aqueous and ethanolic extracts of Ligustrum lucidum Ait. of the Oleaceae Family possess estrogenic properties in both ERα+ and ERβ+ cells. These estrogenic effects include estrogen response element (ERE) stimulation as well as tumor necrosis factor (TNF) repression. Methods are provided for treating climacteric symptoms, breast and / or uterine cancer, and osteoporosis.

Novel methods for treating or reducing the likelihood of acquiring symptoms or diseases due to the menopause, in postmenopausal women, particularly osteoporosis, vaginal atrophy and dryness, hypogonadism, diminished libido, skin atrophy, connective tissue disease, urinary incontinence, breast, endometrial, ovarian and uterine cancers, hot flashes, loss of muscle mass, insulin resistance, fatigue, loss of energy, aging, physical symptoms of menopause, in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor are disclosed. Said method comprising novel ways of administering and dosing dehydroepiandrosterone (DHEA) in order to take advantage of positive androgenic effects in the vaginal layers lamina propia and / or the layer muscularis, without undesirably causing systemic estrogenic effects in order to avoid the risk of breast and uterine cancer. Pharmaceutical compositions for delivery of active ingredient(s) useful to the invention are also disclosed.

Estrogenic extracts of Anemarrhena asphodeloides Bge. from the Liliaceae Family are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.

The invention relates to a medicament for treating acne and comedo. A preparation method of the medicament comprises the following steps of: stir-frying swordlike atractylodes rhizome until the swordlike atractylodes rhizome is yellowish; mixing the stir-fried swordlike atractylodes rhizome and radix rehmanniae, honeysuckle, weeping forsythia, angelica dahurlica, mongolian dandelion herb, gentiana macrophylla pallac, oriental waterplantain rhizome, baical skullcap root, pollen, immature bitter orange and liquorice uniformly; adding the mixture into clear water in an amount which is 3 to 5 times that of the mixture for decocting for 0.5 to 2 hours, and extracting filter liquor, and filtering liquid; and performing subpackage, sterilization and disinfection to prepare oral liquid. The medicament has the advantages of regulating endocrinopathy, excessive endogenous fire and imbalanced androgen and estrogen effectively along with quick response, obvious curative effect, no toxic or side effect and the like.

The invention discloses an application of a dienestrol antibody in an immune electrochemical detection method of simultaneous detection of three female hormone analogous compounds, namely, diethylstilbestrol, dienestrol and hexestrol. The detection method includes following steps: (1) preparing an electrochemical sensor deposited by nano gold and modified by a graphene / strol / chitosan composition; (2) with K3[Fe(CN)6] as a probe, performing the simultaneous detection of the three strol on the basis of a cross immunoreaction of the dienestrol antibody to the three strol. In the method, a detection limit is 0.2 ng / mL and a linearity range is 1-4000 ng / mL of the diethylstilbestrol; the detection limit is 0.05 ng / mL and the linearity range is 10-4000 ng / mL of the dienestrol; and the detection limit is 0.5 ng / mL and the linearity range is 100-4000 ng / mL of the hexestrol.

The invention discloses an anti-osteoporosis acacetin derivative and a preparation method thereof, and belongs to the technical field of pharmaceutical chemistry synthesis. The method comprises the following steps: under the protection of nitrogen, adding acacetin and 2,4-dimethoxy benzyl chloride into an organic solvent, reacting for 6-8 hours under the action of alkali, and carrying out silica gel column chromatography separation and recrystallization to finally obtain the acacetin derivative. According to the invention, pathological experiments find that the acacetin derivative can inhibit bone resorption increase and bone tissue destruction caused by lack of female hormone, can also improve the blood calcium concentration and is beneficial to bone deposition, which indicates that the new compound has a certain prevention and treatment effect on osteoporosis caused by lack of female hormone.

The invention discloses a natural medicine composition for treating involutional depression and non-classical depression and use of the natural medicine composition, and belongs to the technical field of research of natural medicine formulas in compatibility dosage effect and use of the natural medicine. The composition consists of the components in percentage by mass: 70%-97.5% of hippophae rhamnoides fruit oil and 2.5%-30% of pseudo-ginseng stem and leaf total saponins. The natural medicine composition disclosed by the invention is reasonable in compatibility and safe in dosage, is free from any side effects on human bodies, can solve the problems that a conventional medicine has side effects and poor treatment effects when being used for treating climacterium and involutional depression, and has a significant regulation effect on serum marker indexes, namely adenylate cyclase-cyclic adenosine monophosphate and cyclic guanosine monophosphate, and reproductive hormonesm and target acceptors of various impact factors, such as follicular generation promoting hormones, pitocin, dihydrotestosterone hormones, female hormones, adrenocorticotropin hormones, cytokine interleukin-6, interleukin-8 cytokine and interleukin-2, so as to achieve a treatment effect on treatment of the involutional depression and the non-classical depression diseases.

Estrogenic compositions comprising nyasol and analogs thereof are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.

Estrogenic extracts of Anemarrhena asphodeloides Bge. from the Liliaceae Family are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.

An ABC transporter protein expression inhibitor comprising, as the active ingredient(s), 0.001 to 100 nM of one or more members selected from among steroid hormones, compounds having a female hormone function, analogous compounds thereof and antagonistic inhibitors therefor; an anticancer composition containing this ABC transporter protein expression inhibitor and an anticancer drug; and cells useful in the development of an anticancer drug. The present invention provides a drug which inhibits the expression of an ABC transporter to thereby overcome resistance to anticancer drugs; cancer cells useful in screening such drugs; and an anticancer drug efficacious even against such a cancer as having acquired resistance to anticancer drugs.

Extracts of various species of the Moraceae family have estrogenic properties. For example, aqueous and ethanolic extracts of Ligustrum lucidum Ait. of the Oleaceae Family possess estrogenic properties in both ERα+ and ERβ+ cells. These estrogenic effects include estrogen response element (ERE) stimulation as well as tumor necrosis factor (TNF) repression. Methods are provided for treating climacteric symptoms, breast and / or uterine cancer, and osteoporosis.

The invention relates to the field of medicines and particularly relates to a drug-loading material and composition thereof of a sustained-release preparation, the sustained-release preparation and apreparation method therefor. The composition comprises a liposome group and a matrix group which are independently preserved mutually, wherein the liposome group comprises phospholipid and optional cholesterol; the matrix group comprises a matrix, wherein the matrix comprises one or more selected from fatty acid esters, aqueous gel compounds, fat-soluble sustained-release skeleton matrix compoundsand water-soluble sustained-release skeleton matrix compounds; and a weight ratio of the liposome group to the matrix group is 1: (2 to 200). The sustained-release preparation prepared from the composition can stably release drugs at a set release rate, is high in controllability, can achieve large-dose release and can be suitable for serving as an anal sustained-release suppository, thereby being friendlier to skin and safer in use. The sustained-release preparation is particularly suitable for being applied to male hormone drugs or female hormone drugs.

Estrogenic extracts of Astragalus membranaceus Fisch. Bge. Var. mongolicus Bge. of the Leguminosae Family are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor positive cancer, such as estrogen responsive breast cancer. In some embodiments, the methods include treatment or prevention of osteoporosis.

The invention discloses a method for detecting concentration of an estrogen or estrogenic-like compound. The invention discloses a method for detecting the concentration of the compound having estrogenic effect in a sample. The method for detecting the concentration of the compound having estrogenic effect in the sample comprises a step of establishing an estrogen compound concentration-estrogen effect relation curve, wherein, the step comprises a process of preparing two-hybrid yeast saccharomycete liquid of two-hybrid yeast saccharomycete in a logarithmic phase. The method provides the reliable technical means for toxicity detection and risk assessment of environment mixing pollutants.

A traditional condom is made of a rubber thin film without through holes, is watertight, and takes into consideration the fact that bacteria, viruses and microorganisms are cut off so as to avoid cross infection between both a man and a woman. The traditional condom mainly stops sperms from entering a vagina and a uterus, and accordingly the purpose of active contraception is achieved. The traditional condom also has adverse factors, the completely-closed rubber thin film stops body fluid exchange as well, body fluid includes water, protein capable of achieving a lubrication function, small organic molecules, female hormones and male hormones, and an interaction channel of human body bioelectric currents is also cut off. After the traditional condom is used for a long time, adverse effects can be brought to both the man and the woman. A condom with transparent tiny holes can stop bacteria, viruses and microorganisms, body fluid and human body bioelectricity can be transmitted as well, and therefore human health and sexual life harmony can be promoted.

Extracts of various species of the Moraceae family have estrogenic properties. For example, aqueous and ethanolic extracts of Scuttelaria barbata D. Don of the Labiatae Family species possess estrogenic properties in both ERα+ and ERβ+ cells. These estrogenic effects include estrogen response element (ERE) stimulation as well as tumor necrosis factor (TNF) repression. Methods are provided for treating climacteric symptoms, breast and / or uterine cancer, and osteoporosis.

The invention provides a flavonoid derivative for treating osteoporosis as well as a pharmaceutical composition and application thereof. The flavonoid derivative has a chemical structure shown as thefollowing formula A. The structural formula is as shown in the description. The product disclosed by the invention is the flavonoid derivative. The influence of estrogen on the reproductive system does not exist in the human body, but the activity of the estrogen can be increased, and the flavonoid derivative has the characteristic of estrogenic osteoporosis resistance and can achieve effects of reducing bone loss and increasing bone mineral density. The main anti-osteoporosis mechanisms are that (1) osteocyte proliferation can be promoted, bone collagen synthesis and mineralization of the bone matrix can be promoted, and the bone mass is increased; (2) proliferation and differentiation of osteoclast precursor cells can be reduced, the activity of the osteoclast is inhibited, and bone resorption is reduced; and (3) calcitonin secretion is increased by virtue of the estrogenic effect, and bone resorption resistance is indirectly produced.

The invention relates to an enzyme-linked immunosorbent assay (ELISA) kit for detecting trace environmental endocrine disruptor effect and application thereof. The kit comprises a probe, protein, binding buffer solution, an ELISA plate, enzyme mixed liquor I, enzyme mixed liquor II, color developing solution, stop solution, 10*concentrated cleaning solution, and a standard substance. The probe isdouble stranded deoxyribonucleic acid (DNA) marked by biotin for a 5' end; the protein is a recombinant human estrogen receptor; the ELISA plate coats a Ser167 phospho-estrogen receptor monoclonal antibody; and the enzyme mixed liquor I contains two phosphorylating enzymes. By comparing with a standard dosage and effect curve of estradiol, the accumulated estrogenic effect of the environmental endocrine disruptor relative to the estradiol in a sample is determined. The kit is convenient and easy to operate at a high speed, has high flux, and can be widely used in the fields of environment andfood detection and the like.

The invention discloses an anti-osteoporosis Chinese medicinal preparation, which is prepared from the following bulk pharmaceuticals in parts by weight: 4-6 parts of epimedium herb, 4-6 parts of kudzuvine root, 4-6 parts of himalayan teasel root, 1-3 parts of deer horn gelatin and 0.1-0.2 part of oyster. The invention further discloses a preparation method of the anti-osteoporosis Chinese medicinal preparation. The method is easy to operate and implement. A formula for treating post-menopause osteoporosis is obtained according to the conventional kidney-invigorating and bone-supporting theory and the modern plant isoflavone theory. Treatment of osteoporosis with the formula is not reported relatively in the prior art. Each medicinal ingredient in the formula acts in a coordinated way and has the effects of nourishing liver and kidney and strengthening the bones and muscles, and plant isoflavone is used for replacing in-vivo insufficient female hormones, so that double effects are achieved, and good prevention and control effects on post-menopause osteoporosis are achieved.